Novartis

Showing 15 posts of 811 posts found.

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

April 27, 2023
Business Services CHMP, Cosentyx, Dermatology, Novartis

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European …

pm_society

AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

September 20, 2021
Sales and Marketing AstraZeneca, Klarify, Novartis, PM Society Awards, havas life medicom

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the 12th PM Society Digital Awards …

Novartis announce digital collaboration with HPE

June 24, 2021
AI, HPE, Novartis

Swiss pharma company, Novartis, has announced a collaboration with Hewlett Packard Enterprise (HPE), to accelerate its use of data and …

NICE recommends two new treatments for inflammatory arthritis

June 18, 2021
Medical Communications Eli Lilly, NICE, Novartis

NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …

Novartis report longest median OS in breast cancer study

June 3, 2021
Novartis, breast cancer, trials

Novartis has announced updated median overall survival (OS) results for Kisqali (ribociclib), in combination with fulvestrant, in postmenopausal women with …

Novartis eye treatment for diabetics shows positive results in Phase III trial

May 4, 2021
Manufacturing and Production DME, Novartis, diabetic macular edema, macular edema, pharma, pharma news

Novartis’ Beovu treatment for diabetic macular edema (DME) – an eye condition that can cause blindness – has shown positive …

Novartis multiple sclerosis treatment recommended by NICE

April 20, 2021
Manufacturing and Production NICE, Novartis, multiple sclerosis, pharma, pharma news

NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …

Novartis signs capacity and technology transfer agreement for Roche drug

April 15, 2021
Novartis, Roche, production

Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of …

Novartis MS therapy gains MHRA and EC approval

April 8, 2021
European Commission, MHRA, Novartis, pharma, pharma news

The MHRA and European Commission have both granted marketing authorisation to Novartis for its Kesimpta therapy, for the treatment of …

Novartis and Artios Pharma to collaborate on DDR cancer therapies

April 7, 2021
Research and Development Novartis, RLT, oncology

Novartis and Artios Pharma have announced a global research collaboration to discover and validate next generation DNA damage response (DDR) …

Novartis prostate cancer treatment sees positive Phase III results

March 23, 2021
Manufacturing and Production Novartis, oncology

Novartis has today announced positive results from its Phase III VISION study with 177Lu-PSMA-617, seeing significant improvements in overall survival …

novartis_window

Novartis’ canakinumab fails to improve lung cancer survival in Phase III study

March 9, 2021
Manufacturing and Production Cancer, Novartis, lung cancer

Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …

Novartis signs agreement to manufacture CureVac’s COVID-19 vaccine

March 5, 2021
Medical Communications COVID-19, CureVac, Novartis, vaccines

CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the …

Verona Pharma appoints Novartis Gene Therapies VP Lisa Deschamps to its board

March 2, 2021
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, verona, verona pharma

Verona Pharma has appointed Lisa Deschamps, Senior Vice President and Chief Business Officer of Novartis Gene Therapies, as Non-Executive Director …

NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer

February 26, 2021
Medical Communications Cancer, NICE, Novartis

NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …

Latest content